precision medicine

Rapport Therapeutics will present Phase 2a follow-up data for experimental seizure drug RAP-219 at neurology conference in April 2026.

Nuvectis Pharma will present three posters on NXP900, a first-in-class cancer inhibitor, at April's AACR Meeting in San Diego, highlighting combination and immunotherapy potential.

Esophageal cancer market projected to grow 44% to $2.37B by 2030 at 9.5% CAGR, with Pfizer, Roche, and Merck dominating through precision oncology and immunotherapy innovations.

Beam Therapeutics reports positive Phase 1/2 data for BEAM-302 base editing therapy in alpha-1 antitrypsin deficiency, advancing toward pivotal development in late 2026.

RTW Investments purchases $116M stake in Cogent Biosciences, raising position to 2.7% of AUM amid 360% stock surge and anticipated 2026 FDA decision on lead drug.

Boone Capital liquidates entire $13.57M Cogent Biosciences stake despite 372% gain, reallocating to earlier-stage biotech plays like TYRA. Strategic rebalancing in volatile sector.

Novartis acquires SNV4818, a next-gen PI3Kα inhibitor, from Synnovation for $2B upfront plus $1B milestones to treat PIK3CA-mutated breast cancer.

Institutional investors rotate capital to precision oncology biotech as patent cliff pressures Big Pharma. Five clinical-stage companies positioned for M&A amid $303B market opportunity.

GNQ Insilico, an AI and quantum computing drug discovery company, to merge with SPAC $IBAC in $500M deal, targeting Nasdaq listing in Q3 2026.

Tevogen Bio ($TVGN) expands T-cell therapy coverage to 65% of U.S. population and pursues digital care platform acquisition to advance Long COVID treatment.

Global molecular diagnostics market projected to reach $33.51B by 2031 at 10.43% CAGR, driven by precision medicine adoption and genomic testing advances.

Tango Therapeutics grants new employee 367,500 stock options and 60,000 RSUs valued at $11.94 exercise price under inducement plan.

Global genomics services market projected to grow from $7.94B in 2025 to $25.18B by 2035, driven by rising genetic disorder prevalence and precision medicine initiatives.

Boxer Capital invests $9.5M in clinical-stage biotech $TNGX, raising stake to 21.09%, as stock surges 427% amid Gilead partnership momentum.

Precision medicine market expected to double to $237.28B by 2031, driven by AI advances and biomarker development at 13.58% annual growth.

Healthcare digital twins market expected to surge from $2.22B in 2025 to $69.67B by 2035, driven by AI integration and precision medicine adoption.

Perceptive Advisors doubled its Celcuity stake to 5.62% of AUM, making it the fund's second-largest holding. Stock surged 700% YoY ahead of expected FDA approval for lead drug Gedatolisib.

Relay Therapeutics reports 2025 results February 26, highlighting progress on lead drug zovegalisib advancing through Phase 3 trials with FDA Breakthrough Therapy Designation.

Myriad Genetics reports 2025 results February 23, 2026, while preparing March launch of Precise MRD cancer detection product. Strong clinical data supports expansion.

Clinical analytics market projected to grow from $33.09B in 2025 to $81.32B by 2030, driven by EHR adoption, AI advances, and value-based care demand.